Tvardi Therapeutics (TVRD) and Its Competitors Head to Head Contrast

Tvardi Therapeutics (NASDAQ:TVRD) is one of 618 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Tvardi Therapeutics to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Volatility & Risk

Tvardi Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics’ competitors have a beta of 0.97, indicating that their average stock price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Tvardi Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1	3	3	0	2.29
Tvardi Therapeutics Competitors	5222	11834	36891	1104	2.62

Tvardi Therapeutics currently has a consensus price target of $55.50, indicating a potential upside of 1,016.70%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 63.26%. Given Tvardi Therapeutics’ higher possible upside, equities research analysts plainly believe Tvardi Therapeutics is more favorable than its competitors.

Profitability

This table compares Tvardi Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	-678.79%	-565.83%	-66.71%
Tvardi Therapeutics Competitors	-1,407.22%	-643.16%	-28.37%

Institutional and Insider Ownership

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 51.1% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Tvardi Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tvardi Therapeutics	$7.14 million	-$70.87 million	-0.23
Tvardi Therapeutics Competitors	$892.24 million	-$46.16 million	-2.57

Tvardi Therapeutics’ competitors have higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Tvardi Therapeutics competitors beat Tvardi Therapeutics on 9 of the 13 factors compared.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.